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Activating mutations in different domains of the ABCC8 gene-coded sulfonylurea receptor 1 (SUR1)
cause neonatal diabetes. Here we show that a diabetogenic mutation in an unexplored helix preced-
ing the ABC core of SUR1 dramatically increases open probability of (SUR1/Kir6.2)4 channel (KATP)
by reciprocally changing rates of its transitions to and from the long-lived, inhibitory ligand-
stabilized closed state. This kinetic mechanism attenuates ATP and sulfonylurea inhibition, but
not Mg-nucleotide stimulation, of SUR1/Kir6.2. The results suggest a key role for L0 helix in KATP
gating and together with previous ﬁndings from mutant KATP clarify why many patients with
neonatal diabetes require high doses of sulfonylureas.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
ABCC8/KCNJ11-coded KATP [1], stimulated by MgATP/ADP at
the ABC ATPase and inhibited by ATP at the K+ inward rectiﬁer
[2,3], control the metabolism-dependent excitability of pancreatic
b-cells and certain neurons [4,5]. Activating mutations in either
KATP gene cause neonatal diabetes (ND), including severe ND with
neurological abnormalities (see [6–8] and many additional reports
reviewed in [9,10]). How ND mutations in different domains of
SUR1 affect KATP open probability (PO) and inhibition by sulfonyl-
ureas (SU) needs to be better understood.
The ﬁrst functional analysis of ND mutations in the canonical
TMD1-NBD1-TMD2-NBD2 core of SUR1 deﬁned its Mg-
nucleotide-dependent hyperstimulation as the ﬁrst, or A type,
mechanism of pathogenic KATP overactivity [7]. Additional tests
[11] uncovered that hyperstimulated KATP can show reduced
responsiveness to sulfonylureas (SU), thus partly explaining why
many ND patients need SU dozes exceeding those recommended
by the FDA for treatment of adult-onset (type 2) diabetes
(discussed in [9,10]).chemical Societies. Published by E
, (SUR1/Kir6.2)4 channel; ND,
Seattle, WA 98122, United
.A strikingly high percentage of ND mutations map to the L0
linker of the TMD0-L0 gatekeeper module (Fig. 1) that couples
the SUR1 core with the KATP pore and controls its nucleotide-
independent POmax [12,13]. The ﬁrst ND mutation found in the L0
linker, L213R, is in the middle of the hotspot region in the putative
interface helix [14] and causes severe ND with neurological abnor-
malities [7]. We hypothesized that the mutation in the domain not
required for nucleotide binding to SUR1 [12] hyperactivates KATP
through a mechanism that is different from A type mechanism.
Consistent with our hypothesis, the diabetogenic F132L in TMD0
of SUR1 increased KATP activity in the absence of nucleotides [15].
The present study validates the hypothesis and establishes the
kinetic mechanism of KATP hyperactivity and reduced SU
responsiveness.
2. Materials and methods
Genetic and clinical testing showing that the mutation caused ND
by compromising insulin release was described elsewhere [7].
Homology models of the Sav1866-like human SUR1 core and the
KirBac/KirChimera-like human KIR6.2 pore were built as described
previously [11,13]. The mean helical hydrophobic moment was
computed as described earlier [16].
Mutagenesis, sequencing, cell culture and transfections were done
as described earlier [7,11]. Leu-213 is conserved in all SURs. L213R
mutation was introduced into hamster SUR1 cDNA. SUR1L213R orlsevier B.V. All rights reserved.
Fig. 1. A working model of a KATP gating unit. One quarter of KATP complex is
shown for clarity. ND ABCC8 mutations are mapped as balls. The SUR1 core is
shown in a backbone wire presentation. Nucleotides are rendered in licorice style.
KIR6.2 pore-forming domains are presented as ribbons. No high resolution
structural template is available for the N-terminal domain of SUR1 or the KIR N-
tail. L213R and other elements of the model discussed in the text are identiﬁed
using color-coded labels. The model of SUR1/KIR6.2 coupling predicts the KIR-closing
movement of L0 and M0 helices colocalized at the membrane-cytosol interface.
Fig. 2. L213R markedly elevates on-cell PO, does not affect the unitary conductance,
and slightly decreases functional expression of (SUR1/KIR6.2)4 complexes without
altering their labeling with 1 nM 125I-azidoglibenclamide. Inset shows similar
afﬁnity photolabeling of immature, core-glycosylated SUR1L213R vs SUR1 with the
second generation SU, and modestly reduced amount of mature, complex-glycos-
ylated mutants trafﬁcking with colabeled KIR6.2. As was reported earlier, nanomolar
glibenclamide or micromolar tolbutamide abolish labelling by displacing the
photoreactive analogue of glibenclamide which does not label KIR6.2 expressed
without SUR1 [17,18,26], the L0 loop apparently coordinates the photoreactive
group-containing non-sulfonylurea moiety of the drug [22,27], and deleting the N-
terminus of KIR6.2 eliminates its colabeling without disrupting KATP assembly [18]
required for trafﬁcking of either SUR1 or glycosylation site-free KIR6.2 to the plasma
membrane [26,28]. Therefore, normal afﬁnity labeling of SUR1L213R and KIR6.2,
while slightly reduced amount of mature SUR1L213R, suggest that the mutation does
not alter the SU binding site or the direct proximity of L0 to the KIR N-terminal helix,
while slightly reducing KATP trafﬁcking to the plasma membrane; nP 5 for each
bar.
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green ﬂuorescent protein (a transfection marker) in COSm6 cells
lacking any endogenous SUR or KIR.
Expression and SU binding/labeling of mature (complex-glycosyl-
ated, 170 kDa) and immature (core-glycosylated, 140 kDa)
receptors were compared in SUR1L213R/KIR6.2- vs SUR1/KIR6.2-
expressing cells’ membranes isolated and photolabeled with
125I-azidoglibenclamide as described previously [17]. The incorpo-
ration of 125I-azidoglibenclamide into different bands was esti-
mated by densitometry of the autoradiographs and normalized to
the membrane protein concentrations as described earlier [18].
Patch-clamp recording and single-channel kinetics analysis were
done as described previously [7,11,19–21]. The pipette solution
contained (in mM): 145 KCl; 1 MgCl2; 1 CaCl2; 10 HEPES; pH 7.4
(KOH). The multivalent cation-free internal solution contained (in
mM): 140 KCl; 5 EDTA; 5 HEPES; 10 KOH; pH 7.2 (KOH). The bath
intracellular solution contained (in mM): 140 KCl; 1 MgCl2; 5
EGTA; 5 HEPES; 10 KOH; pH 7.2 (KOH). The [Mg2+]i in nucleo-
tide-containing solutions was kept at 0.7 mM. The holding poten-
tial was 40 mV. COSm6 cells have negligible background
currents, permitting measurements of virtually any low mean
KATP currents, I, in the native-like environment of mammalian cell
membranes. Analysis of currents allowed to verify the unitary
current amplitude (i) in the cell-attached mode from all-points
current amplitude histograms and determine the on-cell activity
of N identical channels with the mean PO, N  PO = I  i1. The
Colquhoun–Hawkes test was used to evaluate the channel singu-
larity. POmax determined from single-channel and multi-channel
currents were similar. N from macrocurrent noise analysis re-
ﬂected the density of functional channels in the plasma membrane.
All-points dwell time distributions were used to determine mean
life times of all kinetic states and rates of burst–interburst gating
transitions.
Ligand responses of KATP currents were obtained using an
automated multi-channel rapid solution changer as describedpreviously [7,11,19–22]. To correct the ATP dose responses for par-
tial rundown and/or refreshment of KATP currents the I value in
the presence of each ATP concentration was normalized to the
arithmetic mean of the I values before application of each [ATP]
and after washout. Similar corrections were applied when estimat-
ing the steady-state activity in the presence of other ligands.
Statistical data analysis and curve ﬁtting were done using Origin-
Pro 8 (OriginLab Corporation, Northampton, MA) as described pre-
viously [11,22]. Averaged data were expressed as mean ± S.E. for
nP 5 with error bars equal to S.E. unless otherwise noted. Signif-
icance was evaluated using the unpaired t test. Differences with
values of p < 0.05 were considered to be signiﬁcant.
3. Results and discussion
Fig. 2 shows that L213R dramatically increases the Po in intact
cells while not affecting i and slightly decreasing N. The latter
effect is consistent with the small negative effect of L213R on the
amount of mature receptor, which is in line with observations that
a comparable amphipathic L0 helix of ABCC1 attaches to the mem-
brane [23] and L225P in a less conserved portion of the cytoplasmic
linker of SUR1 does not affect N [24] or surface expression of SUR1
in the same cell line [25]. The results show that L213R can induce
pathogenic currents in intact cells by hyperactivating KATP and
support the notion that possible negative effects of some ND
mutations on N (see also [25]) are overridden by their much stron-
ger effect on PO.
To establish the principal mechanism of pathogenic increase in
on-cell PO it is essential to determine if and how the mutation
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tide inhibition vs Mg-nucleotide stimulation of the same popula-
tion of channels before their signiﬁcant rundown [11]. We
obtained a signiﬁcant number of single mutant and WT KATP
records showing no signiﬁcant rundown over minutes in the multi-
valent cation-free internal solution. Analysis of these records
(Fig. 3) demonstrated that L213R nearly saturates the channel
intrinsic activity, POmax? sO  (sO + sCs)1 [12], by increasing TB
and decreasing TIB, thereby limiting the availability of the long-
lived, inhibitory nucleotide-/SU-stabilized [4,19,29,30] nonconduc-
tive C2 state. The analysis of long, continuous, >3 kHz low-pass
ﬁltered single-channel records was essential for determining
highly signiﬁcant mean life times of all kinetic states in each KATP
and demonstrating that reciprocal changes in rates of transitions to
and from the long-lived closed state is the mechanism of POmax
saturation in the hyperactive KATP.
The mutation destabilizing the closed state with the Mg-
independent micromoilar KD(ATP) [19,21,29] could attenuate ATP
inhibition of macroscopic KATP currents without affecting their
Mg-dependent nucleotide stimulation. To test this prediction we
ﬁrst compared the activities of the same macro-population of
L213R channels in intact cells, in 1 mM MgATP, and in 1 mM ATP
without Mg (Fig. 4A illustrates the protocol) vs similarly recorded
activities of WT channels. We found (Fig. 4B) similarly elevated
activities of mutant KATP on cells and in the quasi-physiologic sub-
membrane [MgATP] and similarly signiﬁcant similar-fold de-
creases in the activities of both channels upon Mg removal. The
results suggested that L213R does not alter the Mg-nucleotide
stimulatory action but compromises the Mg-independent nucleo-
tide inhibition of KATP. Indeed, the steady-state inhibitory ATP
dose–response (Fig. 4C) demonstrated that unlike A type muta-
tions tested earlier under identical experimental conditionsFig. 3. L213R saturates intrinsic activity of KATP by altering its slow gating kinetics.
The top panel shows short segments of records of currents trough single WT and
L213R KATP in inside-out patches in the nucleotide-free internal solution. Here and
in the following ﬁgures, downward deﬂection of the current trace corresponds to
inward current and the horizontal dashed line shows zero KATP current level. The
next panels show the results of analysis of 10 L213R vs 10 WT KATP records like
those shown in the top panel. A burst criterion was 2 ms. Each TIB reﬂected the slow
tau determined from all-points closed time distribution ﬁt, verifying no third,
rundown-indicating component ([19,21], not shown here). The mutation-affected
characteristics and transitions are boxed.[7,11], L213R markedly (20 times) increases IC50(ATP). Thus the
mutation limiting the availability of C2 state opens KATP in the
presence of high intracellular [ATP], even without MgADP. This
biophysical mechanism of KATP hyperactivity, called B type
mechanism for short, explains why pancreatic b-cells in the
L213R patient did not release insulin (remained hyperpolarized)
despite his very high blood glucose [7].
A dose of glibenclamide above the FDA recommended dose
allowed to transfer the L213R patient from insulin injections to
SU therapy [7]. We asked if the mutation attenuates KATP inhibi-
tion by SU despite essentially normal SU binding to SUR1L213R/
KIR6.2 complexes (Fig. 2 inset legend). Our ﬁrst test (Fig. 5A)
indicated reduced inhibition of L213R channels by glibenclamide,
but the slow washout of the second generation SU made it difﬁcult
to estimate its steady-state effect corrected for rundown (see Sec-
tion 2 and similar test for WT KATP in [22]). Therefore we used the
rapidly unbinding SU tolbutamide to quantify the effect of L213R
on KATP inhibition by [SU] saturating its speciﬁc, but not non-spe-
ciﬁc, sites [22,31]. We compared the SU inhibition of L213R vs WT
KATP activity under non-stimulatory conditions, as well as in the
presence of the lowest possible submembrane [MgATP] and the
highest possible [MgADP] in resting b-cells [32,33], as we did ear-
lier for A type mutant KATP [7,11]. We found that unlike A type
mutations, L213R compromises SU inhibition under non-stimula-
tory conditions (Fig. 5B, left bars). While saturation of speciﬁc SU
binding sites with 200 lM tolbutamide reduces spontaneous activ-
ity of WT KATP by about 60% [22,31], the same SU treatment of
L213R channels produces signiﬁcantly smaller inhibition. Thus,
L213R alters the nucleotide-independent component of SU action
by uncoupling its high-afﬁnity binding from the channel closure.
Fortunately for ND patients, even lower [SU] signiﬁcantly
decreased the activity of B type channels in Mg-nucleotides
(Fig. 5B, right bars). This is consistent with ﬁndings that speciﬁc
SU binding releases stimulatory nucleotides, thus abolishing KATP
stimulation [22,34]. This effect unmasks the inhibitory action of
nucleotides less effectively in B type mutant channels because of
their increased IC50(ATP). Thus, the mechanism of reduced SU
responsiveness is fundamentally linked to the mechanism of KATP
hyperactivity.
The established kinetic mechanism of ND-SUR1/Kir6.2 hyperac-
tivity and SU tolerance is consistent with early ﬁndings that SUR1/
DNKir6.2 channels with increased spontaneous activity show
decreased sensitivity to ATP and SU [21,22,35–37] and inhibit insu-
lin secretion in mice [38]. These and additional studies using
chimeric SUR [20], N-terminal Kir6.2 peptides [18], and TMD0-L0
fragments [12] led us to the conclusion that TMD0-L0/M0–M1
interactions play key roles in KATP assembly and gating [13].
Consistent with the proposal, F132L in TMD0 and activating muta-
tions in M0 alter intrinsic gating [15,39,40]. Strong effects of L213R
in L0 helix on TB/TIB and KATP inhibition provide a new evidence in
support of our working mechanistic model (Fig. 1). Only subtle and
insigniﬁcant functional effects of E208K [25] are not surprising.
Unlike L213R, E208K can be carried asymptomatically [41,42]
and exchanges similarly hydrophilic side chains on the hydrophilic
side of the submembrane amphipathic helix (Fig. 6). Normal POmax
and ATP inhibition of SUR1L225P/Kir6.2 channels [24,25] are consis-
tent with the prediction that a relatively short [14] interface L0 he-
lix is a key element of the SUR1/Kir6.2 inhibitory machinery. So, it
is tempting to speculate that L0 helix interacts with the equidistant
[43] M0 ‘‘slide’’ [44] helix (Fig. 6) to lock the ligand-sensitive gate
(Fig. 1). The mechanistic interpretation is consistent with homolo-
gous structures [44–48] and single particle electron microscopy
analysis of (SUR1-KIR6.2)4 [49] verifying that TMD0-L0 gatekeepers
can ﬁt between the KIR tetramer and four SUR1 cores and thus
might transduce signals from the receptor core to the pore
[12,13]. A similar L0 helix was shown to interact with the
Fig. 4. L213R compromises inhibitory nucleotide action. (A) L213R KATP currents under conditions indicated. The vertical arrow marks transition from the cell-attached (on-
cell) to inside-out patch conﬁguration in the intracellular solution. (B) The results from tests like in A (10 different cells for each KATP type). (C) The inhibitory ATP dose–
response curve for L213R (IC50(ATP) = 101.7 ± 4.1 lM; Hill coefﬁcient = 1.19 ± 0.04) vs those for WT and A type mutant KATP tested earlier under similar conditions (see [7,11]
for details); n = 10 and R2 > 0.995 for each curve ﬁt.
Fig. 5. L213R attenuates inhibition of KATP by sulfonylureas. (A) L213R KATP currents indicating their reduced response to the normally (tightly) binding, slowly dissociating,
insulin secretagogue glibenclamide (Glb). Electrophysiological conditions are like in Fig. 4. The vertical arrow marks patch excision in the intracellular solution. (B) The
steady-state inhibition of L213R vs WT KATP by tolbutamide (Tlb) under conditions indicated; n = 10 for each bar.
Fig. 6. Helical wheel plots of L0 and M0 helices. The two helices are in an
antiparallel orientation and their matching hydrophobic moments (vectors) point
toward the membrane. The expected L213R-induced rotation of L0 helix is
indicated.
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(labeling) evidence for the close proximity of ABCC8 L0 to the
N-terminal domain of KIR6.2 in inhibited KATP [18]. L213R does
not alter the direct proximity of L0 to Kir6.2 (Fig. 2 inset), but coulddisrupt optimized L0/M0 interactions by rotating the L0 helix along
its axis (Fig. 6) as L213R changes the helical hydrophobic moment.
The paradigm of evolutionary optimized L0/Kir6.2 interactions
provides a basic explanation for the high concentration of sponta-
neous ND mutations in L0. Although our mechanistic model recon-
ciles available data, it needs to be reﬁned in additional studies.
Further functional analyses of new ND mutations in different
parts of the TMD0-L0 gatekeeper module should shed more light
on functional coupling between SUR1 and Kir6.2 and clarify if most
of these mutations, causing 40% of ND-ABCC8 cases, overactivate
KATP via B type mechanism. Previous studies showed that ND
mutations in every major domain of the ABC core of SUR1 can
increase KATP PO via A type mechanism (reviewed in [9,10]; see
also [25] on V324M in TMD1). As we continue our search for the
third, or C, type diabetogenic mutations altering the SUR1-induced
decrease in the KD for inhibitory ATP [19], it becomes evident that
A and Bmechanisms underlie the majority of ND-ABCC8 cases. This
can explain why most ND-ABCC8 patients require body weight-
normalized SU doses exceeding those prescribed to type 2 diabetes
patients. Pharmacological testing of new ND-ABCC8/KCNJ11
recombinants will help evaluate this argument and identify SU
resistant ND cases requiring alternative personalized therapeutic
approaches.
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